转自：新华财经 8月22日晚，漳州片仔癀药业股份有限公司发布2025年半年度业绩快报，报告期实现营业收入约53.79亿 元，同比下降4.81%；归母净利润约14.42亿元，同比下降16.22%；基本每股收益2.39元。 研发创新方面，片仔癀药业持续强化研发布局，进一步完善研发管线。报告期内，积极推进2个新药立 项，推动18个在研新药及经典名方的研发项目，包括5个中药1.1类、1个中药1.2类以及4个化药1类进入 临床研究阶段。其中，中药1.1类PZH1219（养巢颗粒）获临床许可，PZH1215（芪术糖肾颗粒）完成 Ⅱa期受试者出组；化药1类PZH2111片（实体肿瘤）完成I期受试者入组。 加快"走出去"步伐 勾勒"出海"破局路线图 报告显示，下一步，片仔癀药业将在保障产品市场供给稳定的基础上，不断夯实盈利能力，推动公司经 营质量和综合竞争力迈向新台阶。包括建立原材料价格监测预警机制，优化战略储备体系，平抑成本波 动带来的冲击，增强采购端的抗风险能力；持续跟踪行业政策与市场动态，通过制定差异化的营销策 略，将外部挑战转化为巩固竞争优势、开拓新市场的战略机遇；在生产、运营、管理等各环节深入挖 潜，降本增效，着力 ...

北京盛世康来中药营销策划公司董事长、中国医药健康发展促进专家委员会主任委员申勇对《证券日 报》记者表示，近几年，随着国家政策扶持，中医药类的中华老字号品牌在市场竞争中所产生的影响力 越来越大，老百姓的认可度也越来越高。 1月31日午间，片仔癀公告称，预计2024年第一季度可实现归母净利润同比增长不低于25%。这一增速 引发业内外关注。1月30日晚间，片仔癀公告了2023年业绩快报。数据显示，2023年片仔癀实现营业总 收入100.35亿元，同比增长15.42%；归母净利润27.84亿元，同比增长12.59%。 记者注意到，2023年，片仔癀年营收额首次突破百亿元大关；2024年一季度不低于25%的归母净利润同 比增速，也是公司自2019年以来，历年一季度归母净利润的最大增幅。 片仔癀在相关公告中表示，2023年业绩增长主要系公司核心产品片仔癀系列产品、片仔癀牌安宫牛黄丸 的销售增加；2024年开年以来，公司产品销售势头向好，市场呈现旺销态势，顺利实现了"开门红"。 这样的经营业绩让人眼前一亮，但也有不少投资者对于片仔癀能否实现可持续增长持审慎态度。"片仔 癀属于高端消费，消费者的付费意愿可能较前几年有所降低， ...

据福建漳州片仔癀药业股份有限公司介绍，"片仔癀牌安宫牛黄丸精选道地药材、采用古法工艺、严控 品质。"资料显示，片仔癀药业是以医药制造为主业的中华老字号企业，常年生产片仔癀、安宫牛黄 丸、茵胆平肝胶囊等20多个中成药品种。据悉，片仔癀曾于2014年入选登革热诊疗指南（2014年第2 版），成为推荐中成药之一。 值得注意的是，专家表示，基孔肯雅热可防可控，大家无需恐慌，做好灭成蚊、清积水和防叮咬，可有 效预防基孔肯雅热。诊疗方案中也提到，预防主要措施包括及时清除蚊虫孳生地，降低蚊媒密度；个人 应使用蚊香、驱避剂、蚊帐等方式驱蚊、灭蚊和防蚊；前往基孔肯雅热流行区的旅行者要提高防范意 识，防止在境外感染基孔肯雅热。 转自：新华财经 近期，我国南方个别城市发生基孔肯雅热输入疫情并引发本地传播。国家卫生健康委、国家中医药局印 发基孔肯雅热诊疗方案（2025年版），该版方案从病原学、流行病学、发病机制、临床表现、预防等12 个方面对基孔肯雅热的诊疗给出指导。 根据方案，基孔肯雅热主要通过携带基孔肯雅病毒的伊蚊叮咬传播，目前尚无特异性治疗方法，以对症 支持治疗为主，避免盲目使用抗菌药物，不推荐使用糖皮质激素和免疫球蛋白。 同 ...

Core Viewpoint - Pianzaihuang (600436.SH) has topped the "Hurun Brand List" for five consecutive years but is facing significant challenges, including a slowdown in revenue and profit growth in 2024, attributed to rising raw material costs and a failed pricing strategy [1][2]. Financial Performance - In 2024, Pianzaihuang achieved revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit of 2.977 billion yuan, up 6.42% [2]. - The revenue growth rate for 2024 is the lowest since 2016, with a notable decline in Q4, where both revenue and net profit decreased [2][3]. - Q4 revenue was 2.338 billion yuan, marking a year-on-year decline of 4.92%, while net profit fell by 26.07% [2][3]. Cost Pressures - Rising prices of key raw materials have significantly impacted profit margins, with the price of natural cow bile increasing from 650,000 yuan/kg in January 2023 to 1.65 million yuan/kg by January 2025 [4][5]. - Pianzaihuang's inventory increased by 47.01% year-on-year to approximately 4.987 billion yuan, with raw material inventory growing by about 60% [5]. Pricing Strategy - In May 2023, Pianzaihuang raised the price of its main product, Pianzaihuang pills, by 28.8%, but this led to a decline in sales volume in 2024 [6][7]. - The revenue from the pharmaceutical manufacturing segment was approximately 5.663 billion yuan in 2024, a growth rate lower than the previous year [6][7]. Business Segments - The liver disease medication segment generated about 5.31 billion yuan in revenue, growing 18.98%, while the cardiovascular medication segment saw a revenue increase of only 7.03% [7]. - The cosmetics business, viewed as a secondary growth driver, accounted for less than 10% of total revenue and has shown stagnant growth over the past four years [9]. Regional Performance - Revenue growth varied by region, with the Northeast and North China regions experiencing declines in revenue and gross margin [8]. - The East China region, a key market for Pianzaihuang, saw only a 0.79% increase in revenue, the slowest growth among domestic regions [8].

Core Viewpoint - The company, Pianzaihuang Pharmaceutical Co., Ltd., reported a solid performance in 2024, achieving a consolidated revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit attributable to shareholders of about 2.977 billion yuan, up 6.42% from the previous year [4][5][6]. Group 1: Meeting Procedures and Governance - The 2024 Annual General Meeting (AGM) will be held on June 20, 2025, at 09:00, at the Zhangzhou Xiangjiang Hotel [3]. - The meeting will include a verification of the identity of attendees, and shareholders will have the right to speak, inquire, and vote [2][3]. - Voting will be conducted by registered ballot, with each share representing one vote [2][3]. Group 2: Business Performance - The company achieved a consolidated revenue of approximately 10.788 billion yuan in 2024, representing a 7.25% increase year-on-year [4]. - The net profit attributable to shareholders was about 2.977 billion yuan, reflecting a 6.42% increase compared to the previous year [4]. - The company paid approximately 14 billion yuan in cash dividends, accounting for 50.04% of the net profit attributable to shareholders [9]. Group 3: Honors and Recognition - The company was recognized as one of the "Top 100 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry" and received multiple awards for its brand value and cultural heritage [5][6]. - The company ranked first in the market capitalization of the traditional Chinese medicine industry, with a market value exceeding 120 billion yuan [6]. - The company received various awards, including the "2023 Golden Bull Most Investment Value Award" and "2024 Top 20 ESG Competitiveness in Chinese Pharmaceutical Listed Companies" [6]. Group 4: Research and Development - The company is focusing on enhancing its independent innovation capabilities, with ongoing clinical research on 14 new drug projects [12][13]. - The company has established partnerships with over 10 academicians for collaborative projects, aiming to accelerate technological breakthroughs [13]. - The company is actively involved in national key research projects, enhancing its research capabilities in traditional Chinese medicine [13][14]. Group 5: Future Plans - The company plans to increase its new drug projects and clinical research initiatives, aiming to launch 2-3 new drug projects in the coming year [21]. - The company will focus on expanding its market presence in traditional medicine channels and new consumer markets [21]. - The company aims to enhance its brand visibility through new media and targeted marketing strategies [21].